It’s been an exciting week. My phone hasn’t stopped — patients, colleagues, a couple of surgeons — all asking about the same headline. I’m hopeful there’s more to come soon, so let’s start with where we actually are today.
A patient called my office this week. She’d seen the headline somewhere — “melanoma vaccine,” “breakthrough,” “mRNA” — and by the time she reached me, she’d already decided this might be the answer to something she’d been quietly carrying since her diagnosis. Her question was simple: “Can I get this?”
It’s a fair question. It’s also one I’ve fielded, in some version, from half a dozen patients and two surgeons in the last 48 hours. So rather than answer it once on the phone, I wanted to answer it properly — the way I wish every headline came with an asterisk that read here’s what this actually means.
A quick note on where this comes from: everything above draws on two things — my own experience as an investigator on the earlier phase 2 trial, whose results are already public, and the topline Phase 3 press release issued August 19. I haven’t seen, and I’m not commenting on, any Phase 3 efficacy or safety data beyond what’s been publicly disclosed.
What is it?
The therapy is called intismeran autogene — you’ll also see it written as V940 or mRNA-4157. It isn’t a vaccine in the sense most people mean when they hear the word. It doesn’t prevent melanoma in a patient who has never had a history of melanomas. It’s built after surgery, from the patient’s own tumor. Researchers sequence the mutations unique to the melanoma cancer after it is completely taken by our surgical oncologists, then design an mRNA sequence that teaches the patient’s own immune system to recognize up to 30+ of those specific mutation signatures — training your own T cells (the marines of your body) to go looking for any cancer cells that might be left behind. It’s given alongside pembrolizumab (which essentially takes down the shields that protect cancer cells from the immune attack), the immunotherapy many high-risk melanoma patients already receive today as standard of care after surgery.
How would it actually be given?
In the trial, intismeran was injected into the muscle every three weeks, for up to nine doses, alongside pembrolizumab given by IV infusion periodically— a treatment course that runs a little under a year for most patients. That’s the schedule that was tested, not necessarily what ends up on an eventual label, but it gives a realistic sense of what to expect if this becomes available.
Isn’t that the same technology as the COVID vaccine?
The platform — mRNA — is the same basic idea: give the body a set of instructions and let it build the response. Everything else is different. This isn’t preventive, it isn’t off-the-shelf, and it isn’t given to healthy people. It’s manufactured individually, for one patient, from one tumor.. to teach that patient’s own immune system what to now look for that the immune system initially failed to do in the first place.
What did the new trial actually show?
This is the part worth being precise about. On August 19, Merck and Moderna released topline results from the Phase 3 INTerpath-001 trial — 1,137 patients with completely resected, high-risk melanoma (stage IIB, IIC, III, or IV), randomized to intismeran plus pembrolizumab versus pembrolizumab alone. At a prespecified interim analysis, the trial hit its primary endpoint — recurrence-free survival — and a key secondary endpoint, distant metastasis-free survival. The companies describe the improvement as statistically significant and clinically meaningful. No new safety signals were reported.
What they haven’t released yet is the number itself — the hazard ratio, the actual magnitude of benefit. That’s expected at a future medical meeting, and I’m hopeful it’ll be ESMO this fall — that’s the meeting I think most of us in the field will be watching. I can’t confirm that’s where it’s landing, so take that as my own hope rather than a confirmed date, but it’s the one I’d circle on the calendar.
Does “positive results” mean it improves survival?
Worth slowing down here, because this is where headlines get ahead of the data. Recurrence-free survival and distant metastasis-free survival are both meaningful — they tell us fewer patients saw their cancer come back or spread. But overall survival, the endpoint most people actually mean when they ask “will this help me live longer,” is a separate measure, and in this trial it isn’t mature yet. That’s not a red flag. Five-year data from the earlier phase 2b study behind this program showed a sustained 49% reduction in the risk of recurrence or death, and that trial is still following patients toward its own survival readout. It just means we’re not there yet with the phase 3 data, and I’m not going to tell a patient more than the data currently supports.
Is it available now? Can I get it?
Not yet. This remains investigational — it doesn’t have FDA approval, and the companies have said they’ll be discussing filing with regulators now that the trial has read out. Historically, that process takes time, even on an accelerated track. If I had to guess — and I want to be clear that’s what this is, a guess grounded in how these programs typically move — I’d expect any real path to availability outside a clinical trial to be next year at the earliest if at all.
Where would this fit for patients who’ve already had surgery?
This is the question I’ve heard most from surgical colleagues this week. The trial tested intismeran added on top of pembrolizumab — not as a replacement for existing adjuvant therapy, but as a companion to it. Where it ultimately sits in the treatment sequence, and which patients stand to benefit most, is exactly what the fuller dataset — and the guideline conversations that follow it — will need to sort out.
What’s next?
More data, first. Then regulatory conversations. Then, if all of that goes the way this week’s readout suggests it might, a real conversation about how this reaches patients outside of a trial. I had the chance to serve as an investigator on the earlier phase 2 trial that led here, and the phase 3 program as well, so watching this topline data land hit a little differently for me than most news does. The phase 2 results are public, and what I can tell you from that experience — sitting across from the patients who enrolled — is that a number of them did very well. I don’t have that same window into the phase 3 data; nobody outside the sponsors does yet. But it’s part of why this week’s readout means something a little more personal to me.
That’s really what I want people to take from this: not the headline, and not false hope either, but an honest accounting of where the science actually stands. Melanoma care has changed more in the last decade than in the previous fifty. This might be the next chapter. It might not be the last word. Either way, it’s a good problem to have this many reasons for hope.
Dr. Sajeve Thomas is a distinguished medical professional and a compassionate guide in the field of oncology. With over a decade of dedicated experience as a board-certified medical oncologist/internal medicine specialist, Dr. Thomas has become a trusted expert in the treatment of melanoma, sarcoma, and gastrointestinal conditions. He brings a wealth of expertise to the complex and challenging world of oncology.
Disclosures:
Dr. Thomas serves as a speaker for BMS, Merck, Ipsen, Natera, Immunocore, Pfizer, Sun Pharma, SpringWorks. He also receives industry grants in support of numerous clinical trials.
Leave a Reply